Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm

Sat Jul 13 07:19:22 2024

(2022) Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. Iranian journal of immunology : IJI. pp. 321-329. ISSN 1735-367X (Electronic) 1735-1383 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/36190385

Abstract

BACKGROUND: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). OBJECTIVES: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2. METHODS: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique. RESULTS: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 mug/ml vs. 1.160 mug/ml) and the second (46.68 mug/ml vs. 11.43 mug/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 mug/ml vs. 1.79 mug/ml, p < 0.0001) and the second dose (10. 36 mug/ml vs. 4.88 mug/ml, p < 0.0001). CONCLUSIONS: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.

Item Type: Article
Creators:
CreatorsEmail
Anvari, E.UNSPECIFIED
Ghamar Talepoor, A.UNSPECIFIED
Eshkevar Vakili, M.UNSPECIFIED
Karimi, N.UNSPECIFIED
Ataollahi, M.UNSPECIFIED
Najafi, G.UNSPECIFIED
Kabalitz, D.UNSPECIFIED
Ahmadi, I.UNSPECIFIED
Kalantar, K.UNSPECIFIED
Keywords: Antibodies, Neutralizing Antibodies, Viral Antibody Formation *COVID-19/prevention & control ChAdOx1 nCoV-19 Humans Immunoglobulin G Pandemics/prevention & control SARS-CoV-2 Vaccination *Viral Vaccines
Divisions:
Page Range: pp. 321-329
Journal or Publication Title: Iranian journal of immunology : IJI
Journal Index: Pubmed
Volume: 19
Number: 3
Identification Number: https://doi.org/10.22034/iji.2022.94298.2300
ISSN: 1735-367X (Electronic) 1735-1383 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4059

Actions (login required)

View Item View Item